In this Phase 3 trial, Libtayo demonstrated a significant improvement in overall survival in women with advanced cervical cancer after progression on chemotherapy, reducing the risk of death by 31% compared to chemotherapy in the overall population,” said Krishnansu S. Tewari, M.D., Professor and Director of the Division of Gynecologic Oncology at the University Read more…
KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent (adjuvant) treatment after Read more…
A systematic review and meta-analysis published in JAMA Dermatology identified a potential link between topical calcineurin inhibitors (TCIs) and an increased risk for lymphoma. However, the association did not extend to other forms of cancer, and the absolute risk for lymphoma among users of TCIs remained low. TCIs are used frequently as Read more…
The FDA approved TheraSphere Y-90 Glass Microspheres, a radioembolization technology, for the treatment of patients with hepatocellular carcinoma (HCC), according to a press release. The therapy was previously granted humanitarian device exemption, which limited the number of patients treated with the therapy per year. The technology is a type of selective internal Read more…
For the first time ever, the US Food and Drug Administration (FDA) has approved an immunotherapeutic agent for first-line treatment of gastric cancer. On April 16, the agency approved nivolumab (Opdivo; Bristol Myers Squibb) – in combination with certain types of chemotherapy – for the initial treatment of patients with Read more…
A combination of AstraZeneca’s Imfinzi (durvalumab), tremelimumab and chemotherapy has extended overall survival (OS) when used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). A final analysis of data from the POSEIDON study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus Read more…
Colorectal cancer diagnoses have increased among people under age 50 in recent years, and researchers are seeking reasons why. A new study led by Washington University School of Medicine in St. Louis has found a link between drinking sugar-sweetened beverages and an increased risk of developing colorectal cancer in women Read more…
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker. Read More…